Related Experiment Video
Updated: Jul 17, 2026
12:43
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
Published on: February 21, 2011
Amyotrophic lateral sclerosis: update for family physicians.
Christen L Shoesmith1, Michael J Strong
1London Health Sciences Centre, Ontario, Canada.
Canadian Family Physician Medecin De Famille Canadien
|February 7, 2007
Summary
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder causing muscle weakness. While there is no cure, treatments can enhance survival and quality of life for patients.
Area of Science:
- Neurology
- Neuroscience
Background:
- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motor neuron degeneration.
- It leads to increasing muscle weakness, affecting speech (dysarthria), swallowing (dysphagia), and limb function.
Purpose of the Study:
- To provide a comprehensive overview of amyotrophic lateral sclerosis (ALS).
- Discussing its epidemiology, pathogenesis, diagnosis, clinical course, prognosis, and current treatment strategies.
Main Methods:
- Literature search of PubMed and Cochrane Database of Systematic Reviews.
- Utilized MeSH headings: "amyotrophic lateral sclerosis," "therapy," "epidemiology," and "etiology."
- Review of articles with a focus on the best available evidence (Level I, II, and III).
Main Results:
- ALS presents with progressive dysarthria, dysphagia, and extremity weakness.
- Diagnosis relies on physical examination, electrophysiology, and exclusion of other conditions.
- No cure exists, but available treatments can improve survival and quality of life.
Conclusions:
- ALS is a complex condition requiring specialized management.
- Multidisciplinary clinics offer the optimal approach for comprehensive patient care.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...